Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose Control in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Open Access
- 24 August 2021
- journal article
- review article
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-15
Abstract
Background. Diabetes is a major public health concern. Resveratrol has shown great beneficial effects on hyperglycemia and insulin resistance and as an antioxidant. Methods. We searched the Chinese and English databases (such as CNKI, PubMed, and Embase) and extracted data from randomized controlled trials (RCTs). Then, RevMan 5.3 was used for bias risk assessment and meta-analysis. The primary outcome indicators include insulin-resistance-related indicators and blood-lipid-related indicators. This systematic review and meta-analysis was registered in PROSPERO (CRD42018089521). Results. Fifteen RCTs involving 896 patients were included. For insulin-resistance-related indicators, the summary results showed that, compared with the control group, homeostasis model assessment for insulin resistance (HOMA-IR) in the resveratrol group is lower (WMD: −0.99; 95% CI −1.61, −0.38; ). For blood-lipid-related indicators, the total cholesterol (TC) and triglyceride (TG) in the resveratrol group is of no statistical significance (for TC, WMD: −7.11; 95% CI −16.28, 2.06; ; for TG, WMD: −2.15; 95% CI −5.52, 1.22; ). For adverse events, the summary results showed that there was no statistical difference in the incidence of adverse events between the resveratrol and control groups (WMD: 2; 95% CI 0.44, 9.03; ). Conclusion. Based on the current evidence, resveratrol may improve insulin resistance, lower fasting blood glucose and insulin levels, and improve oxidative stress in patients with type 2 diabetes mellitus.Keywords
Funding Information
- National Natural Science Foundation of China (81700306, 2018JJ3469, 2017M622588)
- Natural Science Foundation of Hunan Province (81700306, 2018JJ3469, 2017M622588)
- China Postdoctoral Science Foundation (81700306, 2018JJ3469, 2017M622588)
This publication has 48 references indexed in Scilit:
- Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic PatientsEvidence-Based Complementary and Alternative Medicine, 2013
- Mechanisms of Diabetic ComplicationsPhysiological Reviews, 2013
- Novel Pharmacological Approaches to the Treatment of Type 2 DiabetesPharmacological Reviews, 2012
- Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activityFood and Chemical Toxicology, 2011
- Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patientsBritish Journal of Nutrition, 2011
- Glycemic Control and Complications in Type 2 Diabetes MellitusThe American Journal of Medicine, 2010
- Safety studies conducted on high-purity trans-resveratrol in experimental animalsFood and Chemical Toxicology, 2009
- Resveratrol addiction: To die or not to dieMolecular Nutrition & Food Research, 2008
- Toxicogenomics of resveratrol in rat liverLife Sciences, 2005
- Oral antihyperglycemic therapy for type 2 diabetes mellitusCanadian Medical Association Journal, 2005